RecruitingPhase 2NCT07501702
A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a Long-term Extension of Povetacicept in Adults With Generalized Myasthenia Gravis
Sponsor
Vertex Pharmaceuticals Incorporated
Enrollment
30 participants
Start Date
May 13, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to evaluate the pharmacodynamic (PD) effect, safety, and tolerability of Povetacicept in participants with generalized myasthenia gravis (gMG).
Eligibility
Min Age: 18 YearsMax Age: 80 Years
Inclusion Criteria2
- Age 18-80 years
- Diagnosis of generalized myasthenia gravis with generalized muscle weakness and fitting MGFA clinical classification II-IV
Exclusion Criteria2
- History of thymic surgery within 6 months of screening
- History of malignancy within the last 5 years
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGPovetacicept
Solution for Subcutaneous Injection.
DRUGPlacebo
Solution for Subcutaneous Injection.
Locations(11)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07501702
Related Trials
Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis
NCT0690925313 locations
Study of Aritinercept in Patients With Generalized Myasthenia Gravis
NCT075969013 locations
Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research
NCT048066201 location
Evaluate the Benefit of Corticoid Sparing in Elderly With Generalized AntiRAch Myasthenia Gravis Treated With IV or SC Efgartigimod
NCT070729881 location
Rituximab EfFicacy IN MyasthEnia Gravis (REFINE)
NCT058688371 location